| (Values in U.S. Thousands) | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 | Apr, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Sanguine Corp (SGUI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sanguine Corp was incorporated in January 27, 1974, in the State of Utah, using the name Sight and Sound Systems, Incorporate. In May of 1992, the Company changed its domicile to the State of Nevada. On June 25, 1993, the Company changed the name to Sanguine Corporation. The Company is engaged in developing oxygen carriers to be used by the medical profession. The Company is conducting research and development to F.D.A. clinical trials. Through the operations of its subsidiary, SGN LifeSciences it is engaged in discovering, developing and commercializing novel biotechnologies that demonstrate significant potential for medical breakthroughs. The company is focused on the development and commercialization of perfluorocarbon based therapeutic oxygen carriers. Its product, PHER-02, is an intravenous perfluorocarbon emulsion that is efficient at dissolving and delivering oxygen to the tissues. It has completed the compounding of PHER-O2, and it has completed initial gross animal tests that do not require regulatory approval prior to commencement. It has also manufactured the experimental doses of PHER-O2 required to conduct these tests. It intend to continue developing the perfluorocarbon compounds in PHER-O2 in order to optimize its quality for intravenous use; and begin animal safety and efficacy trials in accordance with FDA guidelines and comparable foreign regulatory requirements, with the aid and assistance of a regulatory specialist. The Company's main competitors include Alliance Pharmaceuticals, San Diego, California; Oxygen Biotherapeutics, Inc, Durham, NC; Perftoran, Russia. In addition to regulations enforced by the FDA, it may also be subject to regulation under the Occupational Safety and Health Act; the Environmental Protection Act; the Toxic Substances Control Act; the Resource Conservation and Recovery Act; the Comprehensive Environmental Response, Compensation and Liability Act; the National Environmental Policy Act; the Clean Air Act; the Medical Waste Tracking Act; the federal Water Pollution Control Act; and other present and potential federal, state, local and foreign regulations.